Michael J. Newman, Ph.D.

Michael J. Newman, Ph.D.

Company: Decoy Biosystems, Inc.

Job title: Founder and CEO


Dr. Michael Newman has over 35 years of experience carrying out and managing oncology R&D, in addition to undergraduate and graduate research and training in microbiology. His previous positions include faculty appointments in Biochemistry at Brandeis University and the Roche Institute of Molecular Biology, Senior Associate Director of Oncology at Sandoz Pharmaceuticals (world-wide head of Cancer Biology Research), Executive Director of Oncology at Novartis Pharmaceuticals (Head of Cancer Biology Research in the US), and senior management at several early stage Biotechnology companies. Michael received a bachelor’s degree in Biology from the University of California at San Diego, a Ph.D. in Biochemistry and Cellular Biology from Harvard Medical School and carried out post-doctoral research at Cornell University. 


Live Q&A 5:00 pm

Read more

day: Online Conference

Combination Systemic Therapy with a Multiple TLR agonist Safely Eradicates Established Tumors with Induction of Innate and Adaptive Immunological Memory 4:20 pm

• Decoy Biosystems is developing a new and improved systemically administered version of Coley’s Toxins (killed, non-pathogenic, Gram-negative bacteria) that exhibits single agent activity and also synergizes with approved agents to safely eradicate established, solid tumors with induction of innate and adaptive immunological memory • Decoy bacteria are also active in pre-clinical models of chronic…Read more

day: Online Conference

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.